DiaGenic fourth quarter operating revenue increases to NOK 1,078 thousand

January 22, 2016

In the fourth quarter DiaGenic carried out a successful private placement of NOK 70 million and a subsequent repair issue, to shareholders not participating in the private placement of NOK 30 million. Consequently long term financing of the Company was secured. Nominal value per share is NOK 0.05 and the subscription price in both share issues was NOK 0.50 per share.

Operating revenue were NOK 1,078 thousand in fourth quarter 2010 compared with NOK 125 thousand in fourth quarter 2009. Comprehensive income totalled NOK -9.9 million for the fourth quarter in 2010 compared with NOK -11.2 million in the corresponding period in 2009. Total operating costs for the fourth quarter in 2010 amounted to NOK 11.6 million compared with NOK 11.4 million in the fourth quarter in 2009. The company's cash and cash equivalents totalled NOK 98.8 million at 31 December 2010.

Future prospects

? Continue executing on the new companion diagnostics strategy of biomarkers with R&D and licensing agreements within the CNS field with the pharmaceutical and imaging industries aiming for additional partnerships in 2011

? Successfully deliver on the Pfizer collaboration in 2011

? Strengthening and aligning the organization to the new pharma strategy